StockNews.com Begins Coverage on ProPhase Labs (NASDAQ:PRPH)

Investment analysts at StockNews.com started coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

ProPhase Labs Price Performance

ProPhase Labs stock opened at $0.44 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The stock has a market cap of $10.48 million, a price-to-earnings ratio of -0.35 and a beta of -0.37. The firm has a 50-day moving average of $0.55 and a two-hundred day moving average of $1.51. ProPhase Labs has a 1 year low of $0.22 and a 1 year high of $7.48.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PRPH. Renaissance Technologies LLC raised its position in ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock valued at $217,000 after purchasing an additional 71,375 shares in the last quarter. HighTower Advisors LLC grew its position in shares of ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after buying an additional 57,736 shares in the last quarter. Sheets Smith Wealth Management purchased a new position in shares of ProPhase Labs during the fourth quarter valued at $158,000. Geode Capital Management LLC raised its holdings in shares of ProPhase Labs by 26.6% in the fourth quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock valued at $154,000 after acquiring an additional 42,793 shares in the last quarter. Finally, Perritt Capital Management Inc lifted its stake in ProPhase Labs by 129.1% in the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after acquiring an additional 107,068 shares during the period. Institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.